Humanized Anti-Human ERBB3 Recombinant Antibody (TAB-H47)

Customer Review

There are currently no Customer reviews or questions for TAB-H47. Click the button above to contact us or submit your feedback about this product.

Emily Walker
16.Jul,23

Ideal for ERBB3 Studies

The Anti-ERBB3 Antibody (Lumretuzumab) has been excellent for our ERBB3 research. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

John Martinez
12.Dec,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for ERBB3 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Sarah Thompson
08.Sep,21

Consistent and Reliable

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for ERBB3 have been particularly beneficial.

Q&As

1. Is the anti-ERBB3 antibody Lumretuzumab suitable for use in Western blotting?

   A: Yes, the anti-ERBB3 antibody Lumretuzumab (TAB-H47) is suitable for use in Western blotting. It provides specific binding to ERBB3, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-ERBB3 antibody Lumretuzumab?

   A: The recommended storage condition for the anti-ERBB3 antibody Lumretuzumab (TAB-H47) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-ERBB3 antibody Lumretuzumab be used in immunoprecipitation assays?

   A: Yes, the anti-ERBB3 antibody Lumretuzumab (TAB-H47) can be used in immunoprecipitation assays. It provides specific binding to ERBB3, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-ERBB3 antibody Lumretuzumab effective in ELISA applications?

   A: Yes, the anti-ERBB3 antibody Lumretuzumab (TAB-H47) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of ERBB3.

5. What is the optimal dilution for using the anti-ERBB3 antibody Lumretuzumab in immunofluorescence?

   A: The optimal dilution for using the anti-ERBB3 antibody Lumretuzumab (TAB-H47) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Chew, Hui Yi, et al. "Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies." Cell 180.5 (2020): 895-914. https://doi.org/10.1016/j.cell.2020.02.019
   This study explores the use of prochlorperazine (PCZ) to inhibit endocytosis in vivo and enhance the efficacy of therapeutic antibodies targeting cancers. The researchers conducted both preclinical and clinical studies to evaluate the potential of PCZ to block endocytosis temporarily, thereby increasing the availability and effectiveness of antibodies such as cetuximab and trastuzumab on the surface of tumor cells. The study demonstrated that PCZ treatment could significantly enhance antibody-dependent cellular cytotoxicity (ADCC) and improve the therapeutic outcomes in head and neck squamous cell carcinoma (HNSCC) models.
   Creative Biolabs provided humanized monoclonal antibodies for this study, specifically targeting HER3 and IGF-1R. The products included lumretuzumab (Cat# TAB-H47) and dalotuzumab (Cat# TAB-736). These antibodies were used at a final concentration of 60 μg/mL for immunofluorescence and ADCC assays. Lumretuzumab and dalotuzumab played a critical role in the study's examination of antibody internalization and antibody-dependent cellular cytotoxicity (ADCC) in various cancer cell lines, allowing researchers to assess the therapeutic potential and efficacy of these targeted treatments.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H47, RRID: AB_3112034)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Lumretuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lumretuzumab.

Related Diseases

EGFR Tyrosine Kinase Inhibitor Resistance

Related Signaling Pathways

ErbB Signaling Pathway

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "ERBB3"

Select a product category from the dropdown menu below to view related products.